Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Trial of PRAX-114 in Participants With Post-Traumatic Stress Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. DSM-5 diagnosis of PTSD with duration \>6 months, as confirmed by psychiatric evaluation.~2. CAPS-5 total score ≥30 at Screening and Baseline.~3. Body mass index (BMI) of 18 to 38 kg/m2.~Exclusion Criteria:~1. Experienced the index traumatic event before age 16.~2. Has an active legal, worker's compensation, or disability claim for PTSD.~3. Lifetime history of bipolar disorder, a psychotic disorder (eg, schizophrenia or schizoaffective disorder), or obsessive-compulsive disorder or a history of a psychotic mood episode in last 2 years.~4. HAM-D17 score of \>18 at Screening or Baseline.~5. Any current psychiatric disorder (other than PTSD).~6. Lifetime history of seizures, including febrile seizures.~7. Daily consumption of more than 2 standard alcohol-containing beverages for males or more than 1 standard alcohol-containing beverages for females.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Double-blind PRAX-114 (Type: EXPERIMENTAL): Double-blind period - 40 or 60 mg PRAX-114 once daily in the evening
- Double-blind Placebo (Type: PLACEBO_COMPARATOR): Double-blind period - placebo once daily in the evening
- Open-label Extension PRAX-114 (Type: EXPERIMENTAL): Open-label extension period - 40 mg PRAX-114 once daily in the evening

Based on this trial design, predict the completion outcome and termination type (if applicable).